Open AccessAtrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
Author(s) -
William J. Archibald,
Kari G. Rabe,
Brian Kabat,
Joerg Herrmann,
Wei Ding,
Neil E. Kay,
Saad S. Kenderian,
Eli Muchtar,
José F. Leis,
Yucai Wang,
Asher ChananKhan,
Susan M. Schwager,
Amber Koehler,
Amie Fonder,
Susan L. Slager,
Tait D. Shanafelt,
Timothy G. Call,
Sameer A. Parikh
Publication year - 2020
Publication title -
annals of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.079
H-Index - 80
eISSN - 1432-0584
pISSN - 0939-5555
DOI - 10.1007/s00277-020-04094-3
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , hazard ratio , atrial fibrillation , hematology , oncology , retrospective cohort study , adverse effect , proportional hazards model , heart failure , leukemia , confidence interval
Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described.